Legal & General Group Plc Invests $42,000 in Zai Lab Ltd (ZLAB) Stock
Legal & General Group Plc bought a new position in shares of Zai Lab Ltd (NASDAQ:ZLAB) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,132 shares of the company’s stock, valued at approximately $42,000.
A number of other institutional investors also recently made changes to their positions in the business. Marshall Wace North America L.P. boosted its position in Zai Lab by 3.2% during the third quarter. Marshall Wace North America L.P. now owns 168,626 shares of the company’s stock worth $3,285,000 after purchasing an additional 5,234 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Zai Lab by 2.7% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 208,118 shares of the company’s stock worth $4,054,000 after purchasing an additional 5,473 shares during the period. Bank of Montreal Can bought a new stake in Zai Lab during the third quarter worth approximately $159,000. Northern Trust Corp bought a new stake in Zai Lab during the second quarter worth approximately $224,000. Finally, Citadel Advisors LLC bought a new stake in Zai Lab during the third quarter worth approximately $333,000. 34.48% of the stock is owned by hedge funds and other institutional investors.
ZLAB opened at $30.56 on Monday. Zai Lab Ltd has a 1-year low of $14.29 and a 1-year high of $33.86. The company has a market capitalization of $1.78 billion, a PE ratio of -13.17 and a beta of 1.20.
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Featured Story: Cost of Equity
Want to see what other hedge funds are holding ZLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zai Lab Ltd (NASDAQ:ZLAB).
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.